PYXS
Pyxis Oncology, Inc.
Biotechnology · Healthcare · United States
1.81
close · 2026-10-30
value
5
cheaper than peers5
quality
4
stronger fundamentals4
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 19.59× | 36 |
| cash flow yield, 1 year ago | -26.8% | 26 |
| cash flow yield, latest year | -29.4% | 25 |
| cash flow yield, 2 years ago | -35.8% | 24 |
| cash flow yield, 3 years ago | -44.3% | 20 |
| price to book | 10.06× | 20 |
| earnings yield, 1 year ago | -72.9% | 19 |
| earnings yield, 2 years ago | -102.2% | 15 |
| earnings yield, latest year | -70.7% | 15 |
| earnings yield, 3 years ago | -201.7% | 10 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -812.7% | 25 |
| debt to equity | 155.9% | 16 |
| return on equity | -179.1% | 12 |
3 of 4 measures available
Facts
| market cap | $216M |
| free cash flow | -$23.2M |
| employees | 56 |
| first trade | 2021-10-08 |
| next earnings | 2026-08-13 |
| fundamentals updated | 2026-08-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -1.28 | -1.32 | -1.85 | -3.65 | not reported |
| free cash flow | -$63.5M | -$57.9M | -$77.4M | -$95.7M | not reported |
| net income | -$79.6M | -$77.3M | -$73.8M | -$120.7M | not reported |
| revenue | $13.9M | $16.1M | $0 | $0 | not reported |
| unusual items | $0 | -$21.0M | $0 | not reported | -$6.2M |